Gaining a thorough understanding of the chemical and pharmacological attributes of a drug substance through pre-clinical studies is paramount for providing an effective dosage form for first-in-human clinical trials. Yet often insufficient consideration is given to ‘knowing the compound’ before selecting a presentation for clinical evaluation. In particular, an accurate prediction of an appropriate dose range is vitally important for adopting the most appropriate formulation strategy for the compound. If the formulation is not suitable to deliver the required quantity of the drug then the outcome of the trial may be compromised.
Juniper Pharma Services and XenoGesis work together successfully to provide an integrated bio-pharmaceutics service offering. The unique combined approach helps to remove the gap between ‘chemical’ and ‘biological’ to provide the most effective drug delivery solutions.
The webinar will provide an insight into how our joint, consultative approach to drug development can help in understanding the absorption and clearance characteristics of a drug substance and how these properties will influence dose prediction and selection of an appropriate formulation strategy.
Robert Harris, PhD, CChem, FRSC, Chief Technical Officer, Juniper Pharma Services
Rob has over 30 years experience in the pharmaceutical industry. He started his career in production support roles with Warner Lambert and GSK before spending time in academia as a Research Fellow at the University of Manchester, where his research work involved the development of novel drug delivery systems. For the last 15 years Rob has worked in the contract pharmaceutical development sector, holding senior technical roles with Quay Pharma, Capsugel and Penn Pharma. He is currently Chief Technical Officer with Juniper Pharma Services. He maintains a keen interest in drug delivery and its challenges, with a particular focus on oral delivery of poorly soluble compounds.
Graham Trevitt, PhD, Director (DMPK Consultancy, Modelling and Simulation), XenoGesis
Graham joined XenoGesis in 2015, bringing over 14 years industrial drug discovery experience, as well as a track record of delivering pre-clinical drug candidates in oncology and inflammation through integration of DMPK properties into compound design to increase the probability of success.
Prior to joining XenoGesis, Graham worked at UCB for 8 years before joining Almac Discovery in 2009. As Director of Medicinal Chemistry, he was responsible for medicinal chemistry strategy across all projects including integration of DMPK properties into design and progression of compounds. Whilst at Almac Discovery, Graham directed an allosteric Akt inhibitor project from hit-ID to candidate nomination.
Graham graduated from the University of Nottingham with a PhD in Synthetic Organic Chemistry and went on to complete his Postdoctoral Research at the University of Geneva. His role at XenoGesis includes support of client projects, providing expert interpretation of data including prediction, modelling and simulation of PK and PK-PD.
Who Should Attend?
- Senior biotech executives
- CMC consultants
- Formulation scientists
- Pre-clinical scientists
- Pharmaceutical development directors and department heads
- Senior professionals involved in the early development of new drugs (discovery – pre-clinical – formulation development)
Juniper Pharma Services and XenoGesis
Juniper Pharma Services and XenoGesis provide a consultative approach to ensure the most effective outcomes, helping their clients achieve translation from drug discovery into full development.
Combined expertise in one team gives clients a seamless and comprehensive service all the way through to formulation development and to the clinic.
Together, Juniper Pharma Services and XenoGesis provide a better understanding of a compound’s bioavailability, and a smarter and quicker approach for drug product development. This in turn can reduce cost and add value to development projects.